BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) ...
Vertex's VX-548 shows promising efficacy and safety in neuropathic pain management, potentially outperforming Lyrica. Q3 financials are strong: 6% revenue growth, 87.16% gross profit margin, driven by ...
Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than placebos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results